Increasing prevalence of influenza is expected to provide impetus to influenza diagnostic tests market outlook over the forecast duration. The industry trends are also expected to be influenced with the growing awareness among the population about early influenza diagnosis and effective treatment gains traction.
Influenza is a viral infection that attacks the respiratory system (lungs, throat and nose) and is commonly called the flu. Influenza virus testing is important in clinical management as the results may influence clinical decisions such as whether to initiate antiviral treatment, to implement infection prevention, perform some other diagnostic testing, or take control measures for influenza.
During respiratory illness outbreak in closed settings like hospitals, offices, long-term care facility, summer camp, schools, etc., testing for influenza virus infection can be very helpful in determining if influenza is the cause of the outbreak. Since testing for influenza virus is recommended for all patients with suspected influenza, influenza diagnostic tests industry share has received a potent boost from such tests to confirm or rule out the presence of the virus.
Request sample copy of this report @ https://www.gminsights.com/request-sample/detail/4242
Symptoms of influenza can be similar to those caused by other infectious agents including respiratory syncytial viruses, parainfluenza viruses, rhinoviruses, etc. Influenza can worsen and develop complications, such as bronchitis, pneumonia, asthma flare-ups, ear infection, heart problems etc. which have created urgent need for influenza diagnostic and treatments, adding impetus to influenza diagnostic tests market share.
Some of the major trends that will influence the influenza diagnostic tests market are as follows:
Funding for influenza diagnosis, treatment and research boosting influenza diagnostic tests market growth
Influenza diagnostic tests market trends are changing commendably with increased government initiatives and funding. For instance, the government of South Australia started the 2019 Influenza Immunization Program, under which children with medical risk factors are eligible to receive a funded influenza vaccine, Fluarix Tetra®, for free.
An influenza protection company, Seqirus, recently filed an annual strain update with the FDA to manufacture Flucelvax Quadrivalent, their cell-based influenza vaccine, for the 2019-2020 flu season. The vaccine will use a cell based CVV (candidate vaccine virus) for four influenza strains identified by World Health Organization for the upcoming flu season. Moreover, a next generation infectious disease testing company also, recently received $21.9 million in a government funding, to develop breakthrough flu diagnostic technology.
Make Inquiry about this report @ https://www.gminsights.com/inquiry-before-buying/4242
Research programs are dynamically undertaken to improve human health. Various organizations are stepping forward with research on influenza. For instance, National Institute of Allergy and Infectious Disease has been conducting and supporting research to find improved ways to diagnose, treat and prevent influenza infection, which includes working towards innovating a universal flu vaccine that could provide enduring protection against multiple strains of influenza, such as those that cause seasonal flu as well as emerging forms capable of causing a global pandemic.
Growing prevalence of different types of influenza to expand influenza diagnostic tests market share
Increasing incidences of influenza across the world is driving the influenza diagnostic tests market growth. Among the different types of influenza, Influenza A and B are prevalent communicable respiratory diseases and are caused by infection with a virus, also known as bird flu or avian flu.
Type A can spread from animals to humans, while Type B is only contagious in humans. Types A and B can be equally severe and type C is a mild version of the influenza. In 2018, influenza diagnostic tests for Type A Flu was valued at $779.4 million.
RIDTs (Rapid Influenza Diagnostic Tests) detect influenza A and B viral nucleoprotein antigens in respiratory samplings and produce result in a qualitative format. RIDTs yield results in a clinically relevant time slot of less than 15 minutes. In the U.S., a number of RIDTs are commercially available. Growing adoption for flu diagnosing tests are expected to transform the influenza diagnostic tests market outlook over the forecast timeline.
Rising influenza frequency in the U.S. and rest of the world to boost influenza diagnostic tests market
Influenza annually affects 5%–10% of the population worldwide. Since influenza surveillance has been conducted for years in upper-income, temperate countries, this burden is well documented. Influenza being increasingly understood in middle-income countries and surveillance of the disease is substantially improving during recent years, leading to strengthening of influenza diagnostic tests market.
In the U.S., where influenza incidence is highly documented, The Centers for Disease and Control claims that between 15.4 million and 17.8 million people were affected by influenza in the 2019 flu season nationwide. The current flu season has been milder than last year’s, though there have been more deaths than usual from that milder strain. According to CDC, flu typically kills 12,000-56,000 people in the U.S., every year, which makes it much more crucial to detect and treat influenza on time.
Increasing prevalence of influenza in the U.S. will propel influenza diagnostic tests market growth in North America. Rising initiatives by the government to develop advanced technologies in order to deliver efficient results for influenza testing is another major factor that will escalate influenza diagnostic tests growth in the region. In 2018, the U.S. influenza diagnostic market was valued at $287 million and is further expected to witness substantial growth owing to presence of well-developed healthcare infrastructure, technological advancements and skilled professionals.
The World Health Organization, which keeps track of influenza cases and incidence around the world, has urged nations every year that while they enter the flu seasons, steps should be undertaken to strengthen case management, vaccination of high-risk groups and compliance with infection control measures. As diagnostic testing is a part of infection control, influenza diagnostic tests market is expected to gain momentum with industry size expected to surpass $1.5 billion by 2025.